Videos

Jinan Liu, MD, discusses results from a real-world study exploring patterns and predictors of maintenance therapy use among patients with newly diagnosed ovarian cancer.

Katrine Wallace, PhD, MS, discusses study findings estimating the real-world utilization of second-line maintenance therapy for patients with advanced ovarian cancer in the United States.

Rouslan Kotchetkov, MD, PhD, discusses results from a retrospective review exploring the efficacy and safety of bendamustine plus rituximab for the treatment of MCL in the real-world setting.

Kishan Patel, MD, discusses results from a study evaluating the cost-effectiveness of atezolizumab plus bevacizumab for advanced HCC, concluding that it may be too costly under current pricing.

Christopher Lemmon, MD, discusses results from a study on the cost-effectiveness of adjuvant osimertinib in resected EGFR mutant NSCLC patients, finding that it may have the potential to be cost-effective, given the right financial...

Winston Wong, PharmD, and Stephen Schleicher, MD, MBA, discuss the clinical pathways program at Tennessee Oncology and new value-based care considerations in the era of precision medicine.

David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.

Robinson Ortiz, MD, Oncology Medical Director for Cigna, discusses Cigna’s Integrated Oncology Management Program.

Dea Belazi, PharmD, MPH, President and CEO of AscellaHealth discusses the specialty pharmacy arena, what sets AscellaHealth apart, and why these services are important to manage costly gene therapies.